| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/28/2008 | US20080206270 vaccines that rely on eliciting cellular immune responses, specifically induction of cytotoxic T lymphocytes (CTL), against cancer cells and virus-infected cells via administration of a vaccine comprising a fusion peptide or a modified peptide; derived from antigens PRAME, OFA/iLRP, STEAP and SURVIVIN |
| 08/28/2008 | US20080206269 stimulate the resuscitation of bacteria after true dormancy; cognate receptors, convertases, respective genes and inhibitors or mimetics |
| 08/28/2008 | US20080206268 HA-1 epitopes and uses thereof |
| 08/28/2008 | US20080206267 Inactivation Of Genes Of The Mep Pathway |
| 08/28/2008 | US20080206266 Carbohydrate ligand that specifically binds to a leczyme; nucleic acid sequence encoding a nonclassical MHC class I heavy chain; ability to associate with a beta 2 microglobulin; major histocompatibility complex transplantation molecules |
| 08/28/2008 | US20080206265 Using oligonucleotide immunostimulant mixture with drug; Modification of an immunostimulatory oligonucleotide to optimally present 5' ends dramatically enhances its anti-cancer activity |
| 08/28/2008 | US20080206264 when bound by a highly potent human neutralizing monoclonal antibody specific for a V3 conformational epitope; immunogens for inducing broadly-neutralizing antibodies against HIV-1 as well as antagonists for inhibiting the binding of HIV-1 to the relevant co-receptors |
| 08/28/2008 | US20080206263 Methods and Compositions for Prognosing, Detecting, and Treating Age-Related Macular Degeneration |
| 08/28/2008 | US20080206262 complexing of multiple antigens or proteins in a controlled, multivariable fashion, to one single primary recombinant monoclonal antibody; activate dendritic cells and other cells; bound to one half of a Coherin/Dockerin pair |
| 08/28/2008 | US20080206261 administering RegIII protein or Ins2 protein; expression of the IBD marker was decreased |
| 08/28/2008 | US20080206260 Chimeric Tbp-toxin proteins as mucosal adjuvants for vaccination against neisseriae |
| 08/28/2008 | US20080206259 Unique and specific combinations of polyclonal anti-TNF and anti-IL-6 antibodies directed to cytokines; high-risk patients, including immunocompromised patients such as surgical and other hospitalized patients, low birth weight infants, and burn and trauma victims |
| 08/28/2008 | US20080206258 Novel Tetrahydropyridothiophenes |
| 08/28/2008 | US20080206257 Reducing epithelial toxicity during cancer therapy by administering KGF with e.g. erlotinib, Iressa(TM), canertinib, or a monoclonal antibody against EGFR; side effect reduction of diarrhea, rash |
| 08/28/2008 | US20080206256 Treatments for cancer |
| 08/28/2008 | US20080206255 Antibody cancer immunotherapy |
| 08/28/2008 | US20080206254 human monoclonal antibody of the IgG isotype; preventing and treating cardiovascular disorders; specifically binds to the A2 domain of FVIII |
| 08/28/2008 | US20080206253 inhibitor of p38 beta MAP kinase; interfering RNA, short hairpin RNA, ribozyme, antisense oligonucleotide, or protein inhibitor; monoclonal antibody, a polyclonal antibody, a peptide, or a small molecule |
| 08/28/2008 | US20080206252 Novel Polypeptides, and Nucleic Acids Encoding the Same |
| 08/28/2008 | US20080206251 Methods and Compositions to Treat and Detect Misfolded-SOD1 Mediated Diseases |
| 08/28/2008 | US20080206250 Compositions and methods for the therapy and diagnosis of breast cancer |
| 08/28/2008 | US20080206249 comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides |
| 08/28/2008 | US20080206248 associated with cancerous phenotypes and can be used as a basis for the diagnosis of cancer, cancerous cells or a predisposition to cancer in human subjects, and for the prediction of the efficacy of anti-ErbB2 therapy in cancer patients; insertion mutations as well as point mutations |
| 08/28/2008 | US20080206247 Glycoprotein VI fusion proteins |
| 08/28/2008 | US20080206246 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| 08/28/2008 | US20080206245 Compositions and methods for the therapy and diagnosis of breast cancer |
| 08/28/2008 | US20080206244 Compositions and methods for the therapy and diagnosis of breast cancer |
| 08/28/2008 | US20080206243 administering an effective amount of VEGFR agonist; e.g., VEGF, antibodies directed to Flt1, Flt1 ligands, Flt1 small molecule activators, or Flt1 selective agents in a pharmaceutically acceptable carrier |
| 08/28/2008 | US20080206242 Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies |
| 08/28/2008 | US20080206241 rheumatoid arthritis; e.g., a GM-CSF antibody, and an anti-folate compounds, e.g., methotrexate; but in an amount that does not induce neutropenia |
| 08/28/2008 | US20080206240 Antilymphocyte Antibody Induction |
| 08/28/2008 | US20080206239 modified to remove one or more T-cell epitopes; modified anti HER2, anti Lewis Y antigen, anti IgE or anti TNF antibody; mouse antibody with reduced immunogenicity |
| 08/28/2008 | US20080206238 Angiogenesis-Inhibiting Chimeric Protein and the Use |
| 08/28/2008 | US20080206237 Synergistic Combination Of Xolair/Omalizumab/E25 With Immunosuppressive Agent |
| 08/28/2008 | US20080206236 Polyclonal antibody product |
| 08/28/2008 | US20080206235 Vaccine mixture comprising B7-H4 antagonist for use in prevention and treatment of infection and/or cancer |
| 08/28/2008 | US20080206234 Compositions and methods for the therapy and diagnosis of breast cancer |
| 08/28/2008 | US20080206233 Heavy Chain And Single Domain Antibodies |
| 08/28/2008 | US20080206232 Compositions and Methods For Modulating Pgc-1Beta to Treat Lipid-Related Diseases and Disorders |
| 08/28/2008 | US20080206231 Using herstatin as therapeutic in treatment and prevention of diabetes, cardiac disease, diabetes-associated vascular disease, atherosclerosis, hypertension, obesity, lipid metabolism obesity and neurodegenerative disorders |
| 08/28/2008 | US20080206230 Peptides Derived from Human Bplp Protein, Polynucleotides Coding for Said Peptides and Antibodies Directed Against Said Peptides |
| 08/28/2008 | US20080206229 Modified Antibodies Recognizing Receptor Trimers or Higher Multimers |
| 08/28/2008 | US20080206219 Using cytokine modulators as therapeutic tools in treatment of vascular permeability disorders |
| 08/28/2008 | US20080206214 Inhibition of pathogens by probiotic bacteria |
| 08/28/2008 | US20080206207 Intracoronary Device And Method Of Use Thereof |
| 08/28/2008 | US20080206196 Differentiation of cord blood into neural like cells, and method to treat neurological condition patients |
| 08/28/2008 | US20080206194 Inducing estrogen receptor-alpha expression by administering peroxisome proliferator-activated receptor gamma (PPAR gamma) antagonist |
| 08/28/2008 | US20080206190 Glycosylated IL-7, Preparation And Uses |
| 08/28/2008 | US20080206148 Imaging and destruction of malignant tumors using immunoimaging agents comprising nanoclusters incorporating monoclonal antibodies that selectively bind to the cell membrane of tumor cells; conjugates include an encapsulated near-infrared (NIR) fluorescing crystal; tissue-targeted treatment |
| 08/28/2008 | US20080206146 Capable of crossing the blood brain barrier and having differential affinity for a tissue in the brain, such as diseased tissue; diagnosis; drug screening with animal model |
| 08/28/2008 | US20080206143 Blockade of Elr+Cxc Chemokines as a Treatment For Inflammatory and Autoimmune Disease |
| 08/28/2008 | US20080206140 Antibodies specific to malignant cancer specific proliferating cell nuclear antigen (csPCNA) and not to the non-malignant proliferating cell nuclear antigen (nmPCNA) isoform; cancer diagnosis, prognosis, tumor detection and therapy; immunoassay kit |
| 08/28/2008 | US20080206133 Patient-specific anticancer monoclonal antibodies for staging and diagnosis of a cancer, treating tumors and metastases; monoclonal antibody produced by hybridoma; conjugates with cytotoxic agents for tissue-targeted therapy |
| 08/28/2008 | US20080206132 Cancerous Disease Modifying Antibodies |
| 08/28/2008 | CA2717656A1 Activation of human antigen-presenting cells through clec-6 |
| 08/28/2008 | CA2715919A1 Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1) |
| 08/28/2008 | CA2714335A1 Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
| 08/28/2008 | CA2679016A1 Solid pharmaceutical and vaccine dose |
| 08/28/2008 | CA2678966A1 Chimeric newcastle disease virus vlps |
| 08/28/2008 | CA2678963A1 Prevention and treatment of synucleinopathic and amyloidogenic disease |
| 08/28/2008 | CA2678863A1 Engineered anti-il-23p19 antibodies |
| 08/28/2008 | CA2678749A1 Engineered anti-il-23p19 antibodies |
| 08/28/2008 | CA2678618A1 Modulation of nkt cell activity with antigen-loaded cd1d molecules |
| 08/28/2008 | CA2678493A1 Methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease |
| 08/28/2008 | CA2678409A1 Inoculation of recombinant viral vectors for rapid pre-exposure prevention and post-exposure protection against alphavirus-induced encephalitides |
| 08/28/2008 | CA2678304A1 Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins |
| 08/28/2008 | CA2677023A1 Method of purification of hydrophobic proteins |
| 08/28/2008 | CA2675262A1 Compositions comprising polysaccharide conjugates and their use as vaccines |
| 08/27/2008 | EP1962094A1 Detecting agent and therapeutic agent for highly malignant breast cancer |
| 08/27/2008 | EP1961820A2 Lage-1 tumor associated nucleic acids |
| 08/27/2008 | EP1961819A2 Composition and methods for the therapy and diagnosis of lung cancer |
| 08/27/2008 | EP1961814A1 Recombinant polyvalent vaccine |
| 08/27/2008 | EP1961811A1 Novel cytokine ZCYTOR17 ligand |
| 08/27/2008 | EP1961768A1 Recombinant IL-18 Antibodies useful in Treatment of IL-18 mediated Disorders |
| 08/27/2008 | EP1961767A2 Diagnosis and treatment of cancers and other conditions |
| 08/27/2008 | EP1961761A1 Novel peptide compound |
| 08/27/2008 | EP1961428A1 SC6 antibody for treatment of cancer |
| 08/27/2008 | EP1961427A2 Neisserial vaccine compositions comprising a combination of antigens |
| 08/27/2008 | EP1961426A1 Combined meningitis vaccines |
| 08/27/2008 | EP1960778A2 Method for demonstrating presence or absence of markers associated with the presence and/or the chemosensitivity of tumors |
| 08/27/2008 | EP1960549A1 Fc polymorphisms for predicting disease and treatment outcome |
| 08/27/2008 | EP1960527A2 Methods for generating antigen-specific effector t cells |
| 08/27/2008 | EP1960434A2 Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 |
| 08/27/2008 | EP1960432A2 Biological materials and uses thereof |
| 08/27/2008 | EP1960431A1 Use of effector-function-deficient antibodies for treatment of auto-immune diseases |
| 08/27/2008 | EP1960428A1 Antibodies against amyloid beta 4 with glycosylated in the variable region |
| 08/27/2008 | EP1959997A2 Antagonists of hmgb1 and/or rage and methods of use thereof |
| 08/27/2008 | EP1959996A2 Monoclonal antibody |
| 08/27/2008 | EP1959995A1 Therapeutic uses of a3 adenosine receptor antibodies |
| 08/27/2008 | EP1959994A2 Botulinum nanoemulsions |
| 08/27/2008 | EP1959993A2 Multivalent immunoglobulin-based bioactive assemblies |
| 08/27/2008 | EP1959992A2 Novel composition |
| 08/27/2008 | EP1959991A2 Therapeutic vaccine |
| 08/27/2008 | EP1959990A2 Pqs and its conjugates as adjuvants and their uses in pharmaceutical compositions |
| 08/27/2008 | EP1959989A2 Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions |
| 08/27/2008 | EP1959979A1 Methods for promoting neurite outgrowth and survival of dopaminergic neurons |
| 08/27/2008 | EP1959974A2 Modifying leukocyte function |
| 08/27/2008 | EP1521774B1 Truncated tau proteins |
| 08/27/2008 | EP1440156B1 Antigens and vectors for vaccination |
| 08/27/2008 | EP1384726B1 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides |